Corporate Presentation

International Growth Strategy First Move: Australia and Asia Pacific Growth strategy to expand to Australia provides ability to service Asia Pacific markets Actively engaging in opportunities to commence importing and exporting of medical cannabis where federally permissible MediPharm Labs is majority holder (80%) of subsidiary MediPharm Labs Australia Pty. Ltd. Land has been purchased and construction is underway at the MediPharm Labs Australia facility, the first step in the Company's international growth strategy. MediPharm Labs Australia working with 25 Cultivation partners providing options for significant supply inputs Manufacturing licence application currently being reviewed by the Australian Office of Drug Control. Facility is expected to be operational in H2 2019 pending licensing Australia site expected to act as an import and export hub, subject to licensing, until such time as Australian domestic-patient-demand warrants dedicated production activities, 1 hour south-east of Melbourne Corporate Organizational Chart MEDIPHARM LABS CORP. (ON) PUBLICLY TRADED COMPANY MEDIPHARM LABS INC. (ON) LICENSED COMPANY 100% 100% MPL PROPERTY HOLDINGS INC. (ON) HOLDING PROPERTY 80% MEDIPHARM LABS AUSTRALIA PTY. LTD. (AUSTRALIA) MediPharm Labs | 16

View entire presentation